Human and mouse Ig genes are diversified in mature B-cells by distinct processes known as Ig heavychain CSR (class switch recombination) and Ig variable-region exon SHM (somatic hypermutation). These DNA-modification processes are initiated by AID (activation-induced cytidine deaminase), a DNA cytidine deaminase predominantly expressed in activated B-cells. AID is post-transcriptionally regulated via multiple mechanisms, including microRNA regulation, nucleocytoplasmic shuttling, ubiquitination and phosphorylation. Among these regulatory processes, AID phosphorylation at Ser 38 has been a focus of particularly intense study and debate. In the present paper, we discuss recent biochemical and mouse genetic studies that begin to elucidate the functional significance of AID Ser 38 phosphorylation in the context of the evolution of this mode of AID regulation and the potential roles that it may play in activated B-cells during a normal immune response.
Introduction
Antibodies comprise IgH (Ig heavy chain) and IgL (Ig light chain). The N-terminal V (variable) region of IgH and IgL comprise the antigen-binding portion of antibody molecules, whereas the C-terminal constant region of IgH determines effector functions of the molecule, such as where it goes in the body and which downstream pathways it activates to eliminate antigen. There are three somatic DNA alteration events that enable mammalian B-cells to generate an antibody repertoire with enormous diversity and an array of effector functions. Developing B-cells undergo V(D)J recombination to assemble exons encoding the IgH and IgL V regions from a large set of germline-encoded V, D and J gene segments. The V(D)J exon is assembled just upstream of the IgH Cμ constant region exons, leading to expression of Ig μ heavy chains. Following the productive assembly of an IgL V-region exon, the μ heavy chain and IgL associate to produce IgM, which is expressed as a receptor on the surface of the newly generated B-cell. Thereafter, the B-cells migrate to secondary lymphoid organs, where, upon encountering cognate antigen, they can be activated to undergo two additional genetic alterations of their Ig genes, namely IgH and IgL V-region exon SHM (somatic hypermutation), which diversifies the V(D)J exon further, and IgH CSR (class switch recombination), which allows expression of different IgH constant regions (C H regions) and hence different classes of antibody [1, 2] . Although two distinct processes, CSR and SHM absolutely require both transcription through the relevant Ig loci and AID (activation-induced cytidine deaminase) [3] [4] [5] . AID is a ssDNA (single-stranded DNA)-specific cytidine deaminase, expressed primarily in activated B-cells [6] [7] [8] [9] [10] . Most evidence indicates that AID initiates CSR and SHM by deaminating cytidines to uracils in DNA, although there are other views (see [11] for a review). The present article focuses on the post-translational regulation of AID by phosphorylation during CSR and SHM in B-cells.
Class switch recombination
The IgH V(D)J exon is assembled upstream of the Cμ constant region exons, leading to generation of μ heavy chains. Additional sets of C H exons (Cγ , Cα and Cε) are located 100-200 kb downstream of Cμ. All of the different sets of C H exons that undergo CSR are flanked upstream by large (1-10 kb), repetitive S ('switch') regions, which contain an abundance of so-called SHM motifs (see Figure 1 and below). CSR involves the introduction of DNA DSBs (double-strand breaks) into the 'donor' Sμ region and into a downstream 'acceptor' S region, followed by joining of the donor and acceptor S regions. This CSR process juxtaposes a new downstream set of C H exons in place of the Cμ exons, allowing expression of the V(D)J exon with a different set of C H exons. An activator-and cytokine-specific promoter In vitro, AID preferentially deaminates C residues in DNA to uracil in the context of a WRCY sequence motif (the target of AID within the motif is underlined) [20] [21] . Seven of the eight possible tetranucleotide permutations of this motif conform to the 5 -WRCY-3 /5 -RGYW-3 sequence structure in dsDNA (left); in this context, a single AID-mediated deamination event is possible within each double-stranded motif (as indicated). The palindromic sequence AGCT is unique in that it conforms to the 5 -WRCY-3 /5 -WRCY-3 sequence structure in dsDNA (right); in this context, AID-mediated deamination events are potentially possible on both strands of the DNA duplex within the same double-stranded motif (as indicated). S regions contain a higher density of AGCT motifs than V regions; AGCT motifs are often tandemly repeated within core switch sequences. AID-mediated deamination of C residues at S and V regions in vivo co-opts the activities of the BER and MMR pathways [28] . The BER pathway is apparently the dominant pathway during CSR in vivo; it is thought that uracil-DNA glycosylase removes AID-generated U lesions, leading to subsequent endonuclease cleavage of the phosphodiester bond 5 of the resultant abasic site [29] . AID-mediated deamination of cytosine residues on both DNA strands within the same or neighbouring 5 -AGCT-3 /5 -AGCT-3 motifs and processing of the resultant U lesions via activity of the BER pathway theoretically could lead to the efficient formation of the DSBs that are required for CSR.
precedes each S region. Activation of these 'germline' promoters and transcription through the corresponding S region is required to target CSR [11] . Such transcription directs the activity of AID to the targeted S region, which is essential for initiating the DSB-inducing process ( [12, 13] , but see [13a] ). In this context, mice with targeted deletion of the AID gene or human patients harbouring loss-of-function AID mutations are unable to undergo CSR and express higher levels of IgM antibodies [3, 5] . AID initiates CSR by deaminating cytidine residues in transcribed S regions, leading to the generation of uracil lesions in DNA. The resulting U/G mismatches appear to be converted into DSBs through the coopted activities of the BER (base excision repair) and MMR (mismatch repair) pathways [14, 15] . Once DSBs have been generated in two separated S regions, they are synapsed, apparently in large part by general cellular mechanisms [16] , and joined, predominantly by the non-homologous end-joining pathway, but also by an alternative end-joining pathway [17] .
Somatic hypermutation
During an immune response, the SHM process can introduce substitution mutations at a very high rate (estimated to be ∼10 − 3 -10 − 4 /bp/generation) [18] into the IgH and IgL V-region exons of activated B-cells, ultimately allowing selection of B-cells with increased affinity for antigen [19] . SHM at C/G pairs occurs preferentially at RGYW and WRCY DNA motifs (the mutated position is underlined), which are particularly abundant in the DNA sequences that encode the V-region complementarity-determining regions, the site of the majority of the antigen contact residues. Biochemical studies suggest that the WRCY motif is a preferential target for AID (Figure 1 ) [20] [21] [22] [23] . In this context, CSR regions are also particularly rich in such motifs, most notably the AGCT sequence. SHM requires transcription, with mutations starting from approx. 100-200 bp downstream of the V exon promoter and extending 1.5-2 kb downstream, generally sparing the C H exons. SHM also occurs at significant levels in S regions and their immediate flanking sequences during CSR, presumably as a by-product of AID generating S region DSBs [24] . In addition, SHM occurs in certain non-Ig genes, although at much lower levels than in S region and V(D)J exon targets during CSR and SHM [25] [26] [27] . The mechanisms that lead to such precise targeting of AID are still under investigation, although some mechanisms that may help to contribute to this specificity will be a topic of this review. Mice and human patients with loss-of-function mutations of AID fail to undergo SHM, indicating an essential role for AID in this process as well as in CSR [3, 5] . SHM also appears to be initiated by C to U deamination in DNA [2, 11] . AID-generated U lesions in the DNA template transition hypermutations at C/G pairs and also co-opt activities of the BER and MMR pathways (resulting in the generation of the complete spectrum of hypermutations at C/G and A/T pairs) [28, 29] .
Potential mechanisms for AID access to duplexed DNA during CSR and SHM Several potential mechanisms have been elucidated for transcription-dependent AID access to dsDNA (doublestranded DNA) [30] [31] [32] [33] . In the present review, we focus on just two potential mechanisms that have been the focus of studies in our laboratories: one mechanism involves R-loops and the other involves RPA (replication protein A). Other potential mechanisms are mentioned in the last section of the present paper. mAID (mouse AID) has been shown to be a ssDNAspecific cytidine deaminase which deaminates ssDNA substrates in vitro, but does not deaminate dsDNA substrates, except under certain conditions [6, 33] . Several mechanisms have been implicated in AID access to duplex V(D)J exons and S regions in vivo. Because of their high G/C content and G-richness on the non-template strand, mammalian S regions generate ssDNA within R-loops transcribed in the physiological direction [34] [35] [36] . In vitro purified mAID deaminates the non-template strand of T7 RNA polymerase-transcribed dsDNA sequences that form R-loops (e.g. S regions in sense orientation), but not transcribed dsDNA sequences that do not form R-loops [6, 33] . Moreover, gene-targeting experiments showed that optimal S region function in vivo depends on transcriptional orientation, supporting the notion that S region transcription might allow AID access to ssDNA in S regions via R-loop formation. Thus R-loop-forming ability may have evolved in mammalian S regions to enhance AID access during CSR [35] .
Variable region exons do not form R-loops [33] . In vitro assays led to the identification of RPA, a trimeric ssDNAbinding protein involved in replication and repair, as a factor that allowed purified B-cell mAID to deaminate transcribed SHM substrates, which contained repeated AGCT motifs, but which did not form R-loops [33] . The 32-kDa subunit of RPA interacts with purified B-cell mAID, and the AID-RPA complex binds to transcribed WRCY/RGYW-containing DNA in vitro, apparently promoting AID deamination of the substrates predominantly within or near SHM motifs. It has been proposed that the AID-RPA complex may bind to and stabilize ssDNA within transcription bubbles to allow AID to access ssDNA substrates [33] . These overall findings led to the proposal that AID may access transcribed V regions, in the absence of R-loops, via an RPA-dependent mechanism [11, 33] .
Both AID and Ig gene SHM occur in bony fish [37] [38] [39] . However, CSR first occurs evolutionarily in amphibians, leading to the suggestion that CSR may have evolved after SHM [40] [41] [42] . XSμ (Xenopus Sμ) is A/T-rich and does not form R-loops when transcribed in vitro [23, 40] . Yet, XSμ can replace mouse Sγ 1 to promote substantial CSR in mouse B-cells [23] . CSR junctions within XSμ in mice occurred in a region of densely packed AGCT sequences in the 5 portion of XSμ; when this sequence was inverted in vivo, CSR junctions tracked with the AGCT motifs. Likewise, the AGCT repeat region was the predominant site of deamination by mAID-RPA in the context of an in vitro transcription-dependent deamination assay, regardless of orientation [23] . On the basis of these findings, it was suggested that CSR evolved from SHM with the early S regions in amphibians being sequences with a high density of SHM motifs that facilitated AID access via an RPA-dependent mechanism. Given that mammalian S regions are also dense in SHM motifs (notably AGCT motifs), these findings further raised the possibility that AID may access mammalian S regions via an RPAdependent mechanism and that R-loop-based mechanisms of access may have arisen later in evolution to facilitate targeting of AID activity further [23] . Because the high density of AID-preferred AGCT motifs appears to target DSBs in XSμ, it seems possible that the higher density of these motifs in IgH S regions compared with Ig V-region exons may contribute to the DSB formation (and hence CSR) or SHM outcome of AID deamination at these sites respectively [11] .
Post-translational modification of AID by phosphorylation
Mammalian AID is phosphorylated on multiple residues. Purified B-cell mAID is phosphorylated at Ser 38 , Tyr   184 and Thr 140 [43] [44] [45] . To date, only the functional significance of Ser 38 phosphorylation has been elucidated in detail. The ability of AID to interact with RPA and function in transcription-dependent dsDNA deamination assays depends on phosphorylation at Ser 38 [33, 43] . The Ser 38 residue exists in a PKA (protein kinase A) consensus motif; accordingly, mAID can be phosphorylated in vitro on Ser 38 by PKA. In addition, a variety of evidence suggests that PKA also phosphorylates mAID on Ser 38 in cells, including activated B-cells [43, 46] . Mouse AID that is not phosphorylated on Ser 38 does not bind RPA and does not mediate dsDNA deamination of transcribed AGCT-rich substrates in vitro [43] , with both activities, however, being restored by in vitro PKA phosphorylation of non-phosphorylated mAID [43] . Correspondingly, a mutant form of mAID in which the Ser 38 residue was changed to alanine (mAID S38A ) retains ssDNA-deamination activity, but lacks the ability to be phosphorylated by PKA and fails to interact with RPA or function in transcription-dependent dsDNA deamination assays [43] . Mouse AID S38A also had reduced CSR activity (15-30% of wild-type activity) in activated AID-deficient B-cells when ectopically introduced via a retroviral expression vector (Figure 2) [43, 44, 46, 47] . Likewise, drug-induced PKA inhibition decreased CSR, and PKA activation via deletion of the PKA negative regulatory subunit increased CSR in vivo [46] . Together, these studies supported a model that proposed that mammalian AID phosphorylation at Ser 38 is a mechanism for augmenting the ability of AID to access S region DNA and initiate CSR. In this context, a similar ex vivo system to test AID SHM activity in mouse B-cells does not exist, but AID S38A was found to have reduced capacity to mediate SHM in substrates introduced into mouse nonlymphoid cells and in Ig genes in chicken DT40 cells [44, 48] .
Despite the strong circumstantial evidence outlined above which points to a potential role for AID phosphorylation during CSR and SHM, this form of AID regulation has been the subject of significant debate. A major argument against this form of AID regulation came from a study that reported that retrovirally driven expression of the AID S38A mutant protein in AID-deficient B-cells restored CSR to nearly wildtype levels [49] . However, given that the AID S38A protein is a hypomorphic mutant with full ssDNA-deamination activity, these apparently discrepant findings might have resulted from overexpression levels that allowed the mutant to 'catch-up' with wild-type activity [43, 44, 46, 47] . In another study, the AID S38A protein purified from insect cell lines appeared to have a similar activity to wild-type AID protein in a transcription-dependent DNA deamination assay [50] . However, in this case, the substrate sequences employed had a high GC content which could generate R-loops upon transcription and allow RPA-independent access via the R-loop mechanism [6, 35] . Another point used to question the role of AID Ser 38 phoshorylation was based on the observation that zAID (zebrafish AID), which lacks a PKA consensus motif and an Ser 38 equivalent residue at the corresponding position to mAID, is able to catalyse robust CSR in mouse B-cells [48, 49] . In this case, however, it was noted that such activity might be provided by a nearby aspartate residue (Asp 44 ), which theoretically could allow zAID to mimic Ser 38 -phosphorylated mAID (Figure 3) . Finally, it was noted that a putative molecular mimic of AID phosphorylated on Ser 38 (replacement of Ser 38 with aspartate to generate AID S38D ) fails to undergo CSR at substantial levels ( Figure 3) [44, 49] . However, it remained possible that this substitution might not fully mimic Ser 38 -phosphorylated AID or might have other unrelated effects on the protein. As discussed in detail in the following sections, each of these questions regarding the physiological role of AID Ser 38 phosphorylation has been addressed recently by either gene-targeted mutation studies [45, 51] or by studying zAID activity in more depth [52] .
Analysis of CSR and SHM in AID S38A -knockin mutant mice
To address the physiological significance of AID phosphorylation at Ser 38 , analysis of a mouse model (in which AID S38A is expressed at physiological levels utilizing its endogenous control elements) was required. Two recent studies reported the generation and analysis of mice expressing only the AID S38A mutant protein, which occurred at levels quite comparable with those of wild-type mAID expression in The PKA phosphorylation site of AID at Ser 38 is present in all organisms that undergo CSR (mammals, amphibians and birds), but is absent from organisms that undergo SHM only (bony fish). The PKA consensus site is represented by 'rrx s / t '. All bony fish AID amino acid sequences contain an aspartate residue, which is absent in the AID amino acid sequences of organisms that undergo CSR.
activated B-cells, from their endogenous AID alleles [45, 51] . In addition, one of these studies also demonstrated that the AID S38A protein expressed from the endogenous AID allele failed to associate with RPA in vivo [51] . Both studies found that mice homozygous for the AID S38A (AID S38A/S38A ) mutation have quite severe CSR defects, demonstrating clearly that the apparently normal levels of CSR reported for this mutant form of AID by others [49] probably resulted from overexpression of the mutant protein as proposed in [47] .
Activation of AID S38A/S38A B-cells with αCD40 and IL-4 (interleukin 4) for 3 days (to induce CSR of Cγ 1) resulted in IgG1 CSR levels that were only 5% of those of wild-type levels, with wild-type levels essentially reaching their maximum values by that day of activation [51] . After 4.5 days of αCD40 and IL-4 treatment, the level of CSR of AID S38A/S38A B-cells reached 40-50% of the wild-type levels, probably reflecting the fact that wild-type B-cells reached their maximum plateau values by day 3.5 and that the AID S38A/S38A hypomorphic mutant B-cells were able to partially 'catch-up' in the intervening 1.5 days of activation [45, 51] . On the other hand, activation of AID S38A/S38A B-cells with bacterial LPS (lipopolysacharride) plus anti-δ-dextran for 3 days (to induce CSR of Cγ 3) led to barely detectable CSR of IgG3 at any of the measured time-points (less than 1% of wild-type levels) [51] . Thus AID S38A/S38A mutant B-cells appear even more severely impaired for CSR of IgG3 than to IgG1. The more severe CSR defect for CSR of IgG3 might reflect several factors, including a lower level of AID expression following LPS plus anti-δ-dextran stimulation [51] (see below for discussion of effects of AID levels on CSR) and/or the smaller size and different sequence of the Sγ 3 target region compared with the Sγ 1 region, which theoretically could make Sγ 3 a poorer AID target [51] .
AID expression has been found to demonstrate haploinsufficiency, with AID +/− B-cells having only about half the level of AID expression as AID +/+ wild-type B-cells [45, 51, 53, 54] . In this context, AID +/− mice also tend to show proportionately reduced CSR [45, 51] ; although in our experiments, we observed this reduction to be more marked for CSR of IgG3 than for CSR of IgG1 [45, 51] (see below). Remarkably, this haploinsufficiency effect was greatly magnified in the context of the AID S38A mutation. Thus AID S38A/− B-cells had dramatically reduced CSR of both IgG1 and IgG3, compared with levels of AID +/− B-cells after 3 or 4.5 days of stimulation for switching either to IgG1 or to IgG3 [45, 51] . In this case, IgG1 CSR of the AID S38A/− B-cells did not exceed 5% of control levels, and CSR of AID S38A/− B-cells to IgG3 were at background AID −/− B-cell levels [45, 51] . The potential significance of the haploinsufficiency phenotype is discussed further below.
The activity of mAID in the transcription-coupled SHM assay in vitro is dependent on phosphorylation at Ser 38 and RPA association and was abrogated by the S38A mutation [43, 52] . It was therefore hypothesized initially that the AID S38A mutation might have a more severe effect on SHM than on CSR, in which AID might still access S region DNA via an R-loop mechanism [11, 33] . However, as mentioned above, no system existed to analyse the effect of the mAID S38A mutation on SHM in B-cells before the generation of AID S38A/S38A mutant mice. Thus the only previous assays to examine the effects of the AID S38A mutation on SHM were performed via the introduction of artificial substrates into fibroblast cells [44] . In contrast with expectations based on the in vitro transcription-dependent deamination assays, analyses of SHM just downstream of the rearranged V(D)J allele in the IgH locus (a standard assay for studying SHM in vivo) revealed that, whereas B-cells from AID S38A/S38A mice had significantly decreased SHM, substantial residual levels (30% of wild-type levels) remained [44] . Therefore, at least on the basis of this particular SHM assay, CSR appears to be more severely impaired in AID S38A/S38A mice than does SHM. However, as observed for CSR in AID S38A/− mutant mice, SHM levels in AID S38A/− were found to be close to background levels and were thus dramatically decreased compared with those of wildtype mice (which were only down approx. 50%) [45] . The latter finding suggests the possibility that, as observed with IgH CSR, SHM levels may also be closely titrated to AID levels in appropriately activated B-cells. If so, by analogy to CSR, more severe effects of the AID S38A mutation might be observed during SHM in particular physiological contexts in which AID induction levels are not as high as in others or in a substrate-dependent manner (e.g. similar to the potentially differing effects of the AID S38A on CSR of Sγ 1 compared with Sγ 3; see above). Of course, it is also possible that there are additional mechanisms that promote AID access, or downstream functions during SHM that are not dependent on Ser 38 phosphorylation (see below for further discussion).
Evolution of AID phosphorylation at Ser 38
Bony fish undergo SHM but do not undergo CSR, potentially because they lack the CSR target sequences (e.g. S regions and different sets of C H exons). In this context, AID from bony fish (e.g. zebrafish and pufferfish) lacks a PKA phosphorylation site corresponding to Ser 38 , but still catalyses CSR following ectopic expression in AID-deficient mouse B-cells [38, 39] . These findings led some to conclude that AID phosphorylation at Ser 38 is not likely to be of physiological relevance [38, 39, 49] . However, AID from all species of bony fish analysed has been found to contain an aspartate residue at position 44 (Asp 44 ) [38, 39] . Biochemical studies revealed that zAID Asp 44 acts as a mimic of the phosphorylated mAID Ser 38 residue with respect to RPA binding and function in the transcription-dependent dsDNA deamination assay [52] . Likewise, the integrity of the AID Asp 44 residue is required for normal CSR; a zAID D44A mutant shows greatly reduced CSR activity, which correlates with loss of ability to bind RPA and loss of activity in the transcription-coupled dsDNAdeamination assay (Figure 2 ) [52] .
These observations led to the hypothesis that bony fish AID represents a 'constitutively active' mimic of Ser 38 phosphorylated AID from higher organisms. Notably, increases in AID activity beyond its physiological levels seem to affect its off-target activities (e.g. initiation of translocations) more dramatically than its on-target activities (e.g. CSR and SHM of Ig genes) [55] [56] [57] [58] . This property may have led to the evolution of precise mechanisms to titrate the level of active AID to better control its physiological activity. Such regulatory mechanisms appear to include a variety of different post-transcriptional modes of control [43, 47, 52, [58] [59] [60] [61] . Notably, amphibians, in which CSR first evolved, as well as higher vertebrates, all express AID that appears to be capable of regulation via Ser 38 phosphorylation. In this context, one speculation is that the evolution of CSR, which involves large numbers of dangerous DNA DSBs, also led to the evolution of more stringent AID control mechanisms, including Ser 38 phosphorylation. A standard method to mimic a phosphorylated serine residue is to convert it into an aspartate residue. In this regard, several groups generated an AID S38D mutant protein and found it to still be impaired with respect to promoting CSR following introduction into AID-deficient activated B-cells [44] , which again has been cited as evidence that Ser 38 phosphorylation has no physiological relevance [49] . However, any amino acid substitution might have adverse negative effects on activity via a variety of different mechanisms (so such an argument is not necessarily valid). On the other hand, if one could indeed make a relevant second site mutation that simultaneously reversed all of the negative biochemical and in vivo CSR effects of the AID S38A mutation, it would be strong evidence in support of the proposed mechanism. Taking a clue from zAID, an aspartate residue was incorporated into the mAID S38A polypeptide at the same relative position (in place of the threonine residue at position 40) as the zAID Asp 44 residue to generate the mAID S38A/T40D double-mutant protein [52] .
Remarkably, the AID T40D mutation substantially reversed the negative biochemical effects of the S38A mutation ( Figure 2 ). Thus the mAID S38A/T40D protein now showed an ability to bind RPA constitutively and thereby catalyse RPAdependent deamination of a transcribed dsDNA substrate in a PKA-phosphorylation-independent fashion. In addition, the mAID S38A/T40D double-mutant protein had significantly increased CSR activity compared with the AID S38A mutant protein. These observations demonstrate that the AID S38A/T40D protein acts like a mimic of AID phosphorylated at Ser 38 both with respect to known biochemical activities and in vivo CSR activity (Figure 2 ) [52] . This linkage of the various biochemical and CSR activities with this second site mutation provides the most compelling evidence to date for the physiological relevance of AID phosphorylation at Ser 38 and resulting RPA interaction. A remaining question, potentially of significant mechanistic interest, is why the AID S38D mutant protein does not regain CSR activity.
Perspective
The clear defects in CSR and, to a lesser extent, SHM of the AID S38A/S38A mutant mice, coupled with the generation of a 'Ser 38 phosphomimetic' form of the mAID protein provide strong evidence in support of a significant physiological role of AID phosphorylation at Ser 38 . Likewise, these studies also strongly support the physiological significance of Ser 38 -phosphorylated AID interaction with RPA to augment AID access to transcribed target DNA sequences. Yet, there are many important unanswered questions regarding this mechanism. One major question is the precise role of Ser 38 phosphorylation in AID regulation. The bulk of AID in activated B-cells is found in the cytoplasm with only a fraction of AID being found in the nucleus [43, 62] . On the other hand, most of the Ser 38 -phosphorylated AID in activated B-cells is found in the nucleus, probably in association with the chromatin fraction of cellular DNA [44] . In this context, it remains to be determined where the PKA phosphorylation of AID occurs within activated B-cells and how it is regulated. In any case, PKA-phosphorylated AID may be preferentially accumulated in the nucleus, perhaps in the context of binding to target DNA via its RPA association. Likewise, the precise role for the evolution of the regulation of AID interaction with RPA via Ser 38 phosphorylation remains to be determined. As outlined above, it appears that the pool of functionally active AID in activated B-cells is quite strictly titrated. Moreover, the effect of small decreases in the level of AID that cannot be phosphorylated on Ser 38 appear disproportionately greater than similar decreases in wild-type AID levels, suggesting that Ser 38 phosphorylation might have a significant role in determining the level of 'active' AID in the cells. It has been speculated that such a level of regulation may be critical to maintain the balance between on-target AID in the context of SHM and CSR compared with off-target activities that could lead to mutations and/or DSBs in other cellular genes that might contribute to transformation [27, 55, 56, 63, 64] . The availability of a mutant AID that appears to behave like a 'constitutively Ser 38 -phosphorylated mimetic' should now allow these notions to be addressed by gene-targeted knockin mutational strategies that will facilitate evaluation of the effects of having all of the endogenous AID in an 'activated' form. IgH CSR appears to be dramatically impaired in AID S38A/S38A mutant B-cells. Residual IgH CSR activity (generally less than 5% of wild-type levels) could be provided by the R-loop mechanism for AID access. However, this raises the question of why R-loops do not provide greater access. Among the possibilities is that the Ser 38 phosphorylation/RPA mode of AID access is important for accessing the template strand (which is hybridized to the germline transcript in a R-loop). Another would be that the RPA bound to S region DNA in the context of the AID-RPA complex has additional functions in recruitment of factors downstream of AID deamination [11, 33] . The relatively high levels of residual SHM in AID S38A/S38A mice raises various questions. First, the SHM levels observed in AID S38A/S38A represent steady-state levels in B-cells that have probably undergone significant selection following the germinal centre response in which SHM occurs. Thus it still remains possible that the actual rate of SHM might be lower than indicated by the steady-state levels. In this regard, we note that, on the basis of kinetics of induction, the actual rate of CSR in AID S38A/S38A activated B-cells appears much less than the steady-state levels observed in activated AID S38A/S38A compared with wild-type B-cells following 4.5 days of induction (see above). On the other hand, there well may be additional mechanisms by which AID accesses transcribed V-region exons in the context of SHM. Studies of genetically modified yeast and DT40 cells have suggested the existence of a R-loop-related mechanism of AID access that relies on factors involved in the processing of nascent RNA transcripts and their release from the DNA template [65] [66] [67] . In addition, other potential modes of generation of ssDNA substrates, including generation of negative supercoiling of transcribed DNA, have been shown to provide AID access to DNA substrates in biochemical assays [30] [31] [32] . Clearly, there is much to be done to elucidate further the mechanisms that target AID to its appropriate substrates and protect other cellular DNA sequences from its highly mutagenic activities. In this regard, none of the postulated mechanisms for AID access appears sufficient to provide the remarkable specificity of AID access to Ig gene SHM and CSR substrates compared with other cellular DNA sequences.
